Почетна › Рак на бели дробови › Јута
Клинички испитувања за Рак на бели дробови во Јута
25 студии за Рак на бели дробови бараат учесници на локации во Јута.
Градови во Јута
Официјален текст на студијата (англиски)
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT06881784SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier
- University of Utah, Salt Lake City
- Veterans Affairs SLC Health Care System (VAMC), Salt Lake City
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст 21 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07460440A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Huntsman Cancer Institute ( Site 0042), Salt Lake City
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07222566A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Huntsman Cancer Institute, Salt Lake City
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07063745Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Utah Cancer Specialists, Salt Lake City
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06712316A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- START Mountain Region, West Valley City
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT06400472AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, West Valley City
Се регрутираФаза 1/2
Возраст од 18 до 75 · Сите полови · Ажурирано 4.9.2026 · NCT07038343Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- Huntsman Cancer Institute, Salt Lake City
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT06343402Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT06500481Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics
- Huntsman Cancer Institute/ University of Utah, Salt Lake City
Се регрутираДобредојдени се здрави волонтери
Возраст од 50 до 80 · Сите полови · Ажурирано 21.7.2026 · NCT07716280A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.6.2026 · NCT07458347Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 3.6.2026 · NCT05642572A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- START Mountain Region, West Valley City
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 28.5.2026 · NCT07223047Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Huntsman Cancer Institute, Salt Lake City
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 15.5.2026 · NCT05379985Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 14.5.2026 · NCT06922591Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 5.5.2026 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Се регрутираФаза 2
18 Minutes · Сите полови · Ажурирано 5.5.2026 · NCT06031688Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 30.4.2026 · NCT05297734A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Huntsman Cancer Institute, Salt Lake City
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 22.4.2026 · NCT07020221Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- University of Utah, Huntsman Cancer Institute, Salt Lake City
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 13.4.2026 · NCT06810544A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- START Mountain Region, West Valley City
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 18.3.2026 · NCT06244771Improving Care for Rural Patients With Solid Tumors
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Се регрутира
Возраст од 18 до 99 · Сите полови · Ажурирано 5.2.2026 · NCT04916990VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Utah Cancer Specialists (site 203), Salt Lake City
Се регрутираФаза 1/2
Возраст од 18 до 80 · Сите полови · Ажурирано 11.12.2025 · NCT03556228SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 28.10.2025 · NCT03452774Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.